{"pmid":32388470,"title":"Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexa COVID-19 direct assay.","text":["Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexa COVID-19 direct assay.","BACKGROUND: So far, one of the major drawbacks of the available molecular assays for the diagnosis of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) is the need for viral nucleic acid extraction from clinical specimens. OBJECTIVE: The aim of this study was to evaluate the performances of a newly designed real-time RT-PCR (Simplexa COVID-19 Direct assay), that is established with an all-in-one reagent mix and no separate extraction required. RESULTS: The lower limit of detection (LOD) for both target genes resulted the same: 3.2 (CI: 2.9-3.8) log10 cp/mL and 0.40 (CI: 0.2-1.5) TCID50/mL for S gene while 3.2 log10 (CI: 2.9-3.7) log10 cp/mL and 0.4 (CI: 0.2-1.3) TCID50/mL for ORF1ab. The LOD obtained with extracted viral RNA for both S gene or ORF1ab was 2.7 log10 cp/mL. Crossreactive analysis performed in 20 nasopharyngeal swabs confirmed a 100% of clinical specificity of the assay. Clinical performances of Simplexa COVID-19 Direct assay were assessed in 278 nasopharyngeal swabs tested in parallel with Corman's method. Concordance analysis showed an \"almost perfect\" agreement in SARS-CoV-2 RNA detection between the two assays, being kappa = 0.938; SE = 0.021; 95% CI = 0.896-0.980. CONCLUSIONS: The high sensitivity and specificity of this new assay indicate that it is promising for laboratory diagnosis, enabling highspeed detection in just over one hour, which is significantly faster than the up to five hours currently required by traditional extraction followed by amplification technologies, thus allowing prompt decision making regarding isolation of infected patients.","J Clin Virol","Bordi, Licia","Piralla, Antonio","Lalle, Eleonora","Giardina, Federica","Colavita, Francesca","Tallarita, Monica","Sberna, Giuseppe","Novazzi, Federica","Meschi, Silvia","Castilletti, Concetta","Brisci, Angela","Minnucci, Giulia","Tettamanzi, Veronica","Baldanti, Fausto","Capobianchi, Maria Rosaria","32388470"],"abstract":["BACKGROUND: So far, one of the major drawbacks of the available molecular assays for the diagnosis of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) is the need for viral nucleic acid extraction from clinical specimens. OBJECTIVE: The aim of this study was to evaluate the performances of a newly designed real-time RT-PCR (Simplexa COVID-19 Direct assay), that is established with an all-in-one reagent mix and no separate extraction required. RESULTS: The lower limit of detection (LOD) for both target genes resulted the same: 3.2 (CI: 2.9-3.8) log10 cp/mL and 0.40 (CI: 0.2-1.5) TCID50/mL for S gene while 3.2 log10 (CI: 2.9-3.7) log10 cp/mL and 0.4 (CI: 0.2-1.3) TCID50/mL for ORF1ab. The LOD obtained with extracted viral RNA for both S gene or ORF1ab was 2.7 log10 cp/mL. Crossreactive analysis performed in 20 nasopharyngeal swabs confirmed a 100% of clinical specificity of the assay. Clinical performances of Simplexa COVID-19 Direct assay were assessed in 278 nasopharyngeal swabs tested in parallel with Corman's method. Concordance analysis showed an \"almost perfect\" agreement in SARS-CoV-2 RNA detection between the two assays, being kappa = 0.938; SE = 0.021; 95% CI = 0.896-0.980. CONCLUSIONS: The high sensitivity and specificity of this new assay indicate that it is promising for laboratory diagnosis, enabling highspeed detection in just over one hour, which is significantly faster than the up to five hours currently required by traditional extraction followed by amplification technologies, thus allowing prompt decision making regarding isolation of infected patients."],"journal":"J Clin Virol","authors":["Bordi, Licia","Piralla, Antonio","Lalle, Eleonora","Giardina, Federica","Colavita, Francesca","Tallarita, Monica","Sberna, Giuseppe","Novazzi, Federica","Meschi, Silvia","Castilletti, Concetta","Brisci, Angela","Minnucci, Giulia","Tettamanzi, Veronica","Baldanti, Fausto","Capobianchi, Maria Rosaria"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388470","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104416","keywords":["rapid response","real-time rt-pcr","sars-cov-2","surveillance"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892649357312,"score":9.490897,"similar":[{"pmid":32276333,"pmcid":"PMC7177594","title":"Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.","text":["Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.","The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID50/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed.","Int J Mol Sci","Yip, Cyril Chik-Yan","Ho, Chi-Chun","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chan, Helen Shuk-Ying","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tam, Anthony Raymond","Chung, Tom Wai-Hin","Chan, Kwok-Hung","Hung, Ivan Fan-Ngai","Cheng, Vincent Chi-Chung","Tsang, Owen Tak-Yin","Tsui, Stephen Kwok Wing","Yuen, Kwok-Yung","32276333"],"abstract":["The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID50/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed."],"journal":"Int J Mol Sci","authors":["Yip, Cyril Chik-Yan","Ho, Chi-Chun","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chan, Helen Shuk-Ying","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tam, Anthony Raymond","Chung, Tom Wai-Hin","Chan, Kwok-Hung","Hung, Ivan Fan-Ngai","Cheng, Vincent Chi-Chung","Tsang, Owen Tak-Yin","Tsui, Stephen Kwok Wing","Yuen, Kwok-Yung"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32276333","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3390/ijms21072574","keywords":["covid-19","covid-19-nsp2 assay","golaymetaminer","sars-cov-2","clinical evaluation","genome subtraction","nsp2","real-time rt-pcr","sensitivity","specificity"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491602337792,"score":457.08304},{"pmid":32388471,"title":"Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting.","text":["Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting.","BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge for diagnostic laboratories around the world. Automation of workflows in molecular diagnostics is instrumental for coping with the large number of tests ordered by clinicians, as well as providing fast-tracked rapid testing for highly urgent cases. In this study we evaluated a SARS-CoV-2 LDT for the NeuMoDx 96 system, a fully automated device performing extraction and real-time PCR. METHODS: A publicly available SARS-CoV-2 RT-PCR assay was adapted for the automated system. Analytical performance was evaluated using in-vitro transcribed RNA and clinical performance was compared to the cobas 6800-based reference assay within the lab. RESULTS: The Envelope (E) Gene-LDT displayed good analytical performance with an LoD of 95.55 cp/mL and no false positives during evaluation of cross-reactivity. A total of 176 patient samples were tested with both the E-Gene-LDT and the reference assay. Positive and negative agreement were 100 % and 99.2 % respectively. Invalid-rate was 6.3 %. CONCLUSION: The E-Gene-LDT showed analytical and clinical performance comparable to the cobas6800-based reference assay. Due to its random-access workflow concept and rapid time-to-result of about 80 min, the system is very well suited for providing fast-tracked SARS-CoV-2 diagnostics for urgent clinical samples in the hospital setting.","J Clin Virol","Norz, Dominik","Fischer, Nicole","Schultze, Alexander","Kluge, Stefan","Mayer-Runge, Ulrich","Aepfelbacher, Martin","Pfefferle, Susanne","Lutgehetmann, Marc","32388471"],"abstract":["BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge for diagnostic laboratories around the world. Automation of workflows in molecular diagnostics is instrumental for coping with the large number of tests ordered by clinicians, as well as providing fast-tracked rapid testing for highly urgent cases. In this study we evaluated a SARS-CoV-2 LDT for the NeuMoDx 96 system, a fully automated device performing extraction and real-time PCR. METHODS: A publicly available SARS-CoV-2 RT-PCR assay was adapted for the automated system. Analytical performance was evaluated using in-vitro transcribed RNA and clinical performance was compared to the cobas 6800-based reference assay within the lab. RESULTS: The Envelope (E) Gene-LDT displayed good analytical performance with an LoD of 95.55 cp/mL and no false positives during evaluation of cross-reactivity. A total of 176 patient samples were tested with both the E-Gene-LDT and the reference assay. Positive and negative agreement were 100 % and 99.2 % respectively. Invalid-rate was 6.3 %. CONCLUSION: The E-Gene-LDT showed analytical and clinical performance comparable to the cobas6800-based reference assay. Due to its random-access workflow concept and rapid time-to-result of about 80 min, the system is very well suited for providing fast-tracked SARS-CoV-2 diagnostics for urgent clinical samples in the hospital setting."],"journal":"J Clin Virol","authors":["Norz, Dominik","Fischer, Nicole","Schultze, Alexander","Kluge, Stefan","Mayer-Runge, Ulrich","Aepfelbacher, Martin","Pfefferle, Susanne","Lutgehetmann, Marc"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388471","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104390","keywords":["covid-19","neumodx","pcr","rapid testing","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892759457792,"score":414.74008},{"pmid":32276116,"pmcid":"PMC7144850","title":"Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay.","text":["Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay.","OBJECTIVE: To evaluate a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and compare it with RT-PCR. METHODS: We designed primers specific to the orf1ab and S genes of SARS-CoV-2. Total viral RNA was extracted using the QIAamp Viral RNA Mini Kit. We optimized the RT-LAMP assay, and evaluated it for its sensitivity and specificity of detection using real-time turbidity monitoring and visual observation. RESULTS: The primer sets orf1ab-4 and S-123 amplified the genes in the shortest times, the mean (+/-SD) times were 18 +/- 1.32 min and 20 +/- 1.80 min, respectively, and 63 degrees C was the optimum reaction temperature. The sensitivities were 2 x 10(1) copies and 2 x 10(2) copies per reaction with primer sets orf1ab-4 and S-123, respectively. This assay showed no cross-reactivity with 60 other respiratory pathogens. To describe the availability of this method in clinical diagnosis, we collected 130 specimens from patients with clinically suspected SARS-CoV-2 infection. Among them, 58 were confirmed to be positive and 72 were negative by RT-LAMP. The sensitivity was 100% (95% CI 92.3%-100%), specificity 100% (95% CI 93.7%-100%). This assay detected SARS-CoV-2 in a mean (+/-SD) time of 26.28 +/- 4.48 min and the results can be identified with visual observation. CONCLUSION: These results demonstrate that we developed a rapid, simple, specific and sensitive RT-LAMP assay for SARS-CoV-2 detection among clinical samples. It will be a powerful tool for SARS-CoV-2 identification, and for monitoring suspected patients, close contacts and high-risk groups.","Clin Microbiol Infect","Yan, C","Cui, J","Huang, L","Du, B","Chen, L","Xue, G","Li, S","Zhang, W","Zhao, L","Sun, Y","Yao, H","Li, N","Zhao, H","Feng, Y","Liu, S","Zhang, Q","Liu, D","Yuan, J","32276116"],"abstract":["OBJECTIVE: To evaluate a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and compare it with RT-PCR. METHODS: We designed primers specific to the orf1ab and S genes of SARS-CoV-2. Total viral RNA was extracted using the QIAamp Viral RNA Mini Kit. We optimized the RT-LAMP assay, and evaluated it for its sensitivity and specificity of detection using real-time turbidity monitoring and visual observation. RESULTS: The primer sets orf1ab-4 and S-123 amplified the genes in the shortest times, the mean (+/-SD) times were 18 +/- 1.32 min and 20 +/- 1.80 min, respectively, and 63 degrees C was the optimum reaction temperature. The sensitivities were 2 x 10(1) copies and 2 x 10(2) copies per reaction with primer sets orf1ab-4 and S-123, respectively. This assay showed no cross-reactivity with 60 other respiratory pathogens. To describe the availability of this method in clinical diagnosis, we collected 130 specimens from patients with clinically suspected SARS-CoV-2 infection. Among them, 58 were confirmed to be positive and 72 were negative by RT-LAMP. The sensitivity was 100% (95% CI 92.3%-100%), specificity 100% (95% CI 93.7%-100%). This assay detected SARS-CoV-2 in a mean (+/-SD) time of 26.28 +/- 4.48 min and the results can be identified with visual observation. CONCLUSION: These results demonstrate that we developed a rapid, simple, specific and sensitive RT-LAMP assay for SARS-CoV-2 detection among clinical samples. It will be a powerful tool for SARS-CoV-2 identification, and for monitoring suspected patients, close contacts and high-risk groups."],"journal":"Clin Microbiol Infect","authors":["Yan, C","Cui, J","Huang, L","Du, B","Chen, L","Xue, G","Li, S","Zhang, W","Zhao, L","Sun, Y","Yao, H","Li, N","Zhao, H","Feng, Y","Liu, S","Zhang, Q","Liu, D","Yuan, J"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32276116","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.cmi.2020.04.001","keywords":["covid-19","detection","rt-lamp","sars-cov-2","visual"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491727118337,"score":405.21304},{"pmid":32462195,"title":"Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2.","text":["Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2.","OBJECTIVES: To evaluate the clinical performance of 3 molecular assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: We used 184 nasopharyngeal swab specimens to compare Abbott ID NOW COVID-19 (Abbott ID NOW), DiaSorin Molecular Simplexa COVID-19 Direct (DiaSorin Simplexa), and Roche cobas 6800 SARS-CoV-2 (Roche cobas) assays. In a separate analysis, 3 specimens (nasopharyngeal, oropharyngeal, and nasal) were collected from 182 unique patients presenting to the emergency department with suspicion of coronavirus disease 2019 and were tested utilizing Abbott ID NOW. To further characterize each assay, relative limits of detection were evaluated utilizing positive nasopharyngeal patient samples. RESULTS: The positive percent agreement was 91% (95% confidence interval [CI], 0.76-0.97) for Abbott ID NOW and 100% (95% CI, 0.90-1.00) for DiaSorin Simplexa and Roche cobas. The negative percent agreement was 100% (95% CI, 0.98-1.00) for all 3 assays. All swab types tested with the Abbott assay produced concordant results. Polymerase chain reaction assays had approximately 10 to 100 times lower limits of detection than Abbott ID NOW. CONCLUSIONS: Based on these evaluations, a multiplatform testing approach is proposed, depending on patient population and assay sensitivity, to address testing needs during a public health emergency.","Am J Clin Pathol","Cradic, Kendall","Lockhart, Marie","Ozbolt, Patrick","Fatica, Lisa","Landon, Lorie","Lieber, Michael","Yang, David","Swickard, Juanita","Wongchaowart, Nicholas","Fuhrman, Susan","Antonara, Stella","32462195"],"abstract":["OBJECTIVES: To evaluate the clinical performance of 3 molecular assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: We used 184 nasopharyngeal swab specimens to compare Abbott ID NOW COVID-19 (Abbott ID NOW), DiaSorin Molecular Simplexa COVID-19 Direct (DiaSorin Simplexa), and Roche cobas 6800 SARS-CoV-2 (Roche cobas) assays. In a separate analysis, 3 specimens (nasopharyngeal, oropharyngeal, and nasal) were collected from 182 unique patients presenting to the emergency department with suspicion of coronavirus disease 2019 and were tested utilizing Abbott ID NOW. To further characterize each assay, relative limits of detection were evaluated utilizing positive nasopharyngeal patient samples. RESULTS: The positive percent agreement was 91% (95% confidence interval [CI], 0.76-0.97) for Abbott ID NOW and 100% (95% CI, 0.90-1.00) for DiaSorin Simplexa and Roche cobas. The negative percent agreement was 100% (95% CI, 0.98-1.00) for all 3 assays. All swab types tested with the Abbott assay produced concordant results. Polymerase chain reaction assays had approximately 10 to 100 times lower limits of detection than Abbott ID NOW. CONCLUSIONS: Based on these evaluations, a multiplatform testing approach is proposed, depending on patient population and assay sensitivity, to address testing needs during a public health emergency."],"journal":"Am J Clin Pathol","authors":["Cradic, Kendall","Lockhart, Marie","Ozbolt, Patrick","Fatica, Lisa","Landon, Lorie","Lieber, Michael","Yang, David","Swickard, Juanita","Wongchaowart, Nicholas","Fuhrman, Susan","Antonara, Stella"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462195","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/ajcp/aqaa097","keywords":["abbott id now","covid-19","coronavirus","molecular diagnostics","sars-cov-2"],"locations":["Abbott"],"topics":["Diagnosis"],"weight":1,"_version_":1668079521248575489,"score":375.8708},{"pmid":32353760,"pmcid":"PMC7195328","title":"Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2.","text":["Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2.","BACKGROUND: Numerous nucleic acid amplification assays have recently received emergency use authorization (EUA) for the diagnosis of SARS-CoV-2 infection, and there is a need to assess their test performance relative to one another. OBJECTIVES: The aim of this study was to compare the test performance of the Hologic Panther Fusion SARS-CoV-2 assay targeting two regions of open reading frame 1ab (ORF1ab) to a high complexity molecular-based, laboratory-developed EUA from Stanford Health Care (SHC) targeting the SARS-CoV-2 envelope (E) gene. STUDY DESIGN: We performed a diagnostic comparison study by testing nasopharyngeal samples on the two assays. Assay agreement was assessed by overall percent agreement and Cohen's kappa coefficient. RESULTS: A total of 184 nasopharyngeal samples were tested using the two assays, of which 180 showed valid results and were included for the comparative analysis. Overall percent agreement between the assays was 98.3 % (95 % confidence interval (CI) 95.2-99.7) and kappa coefficient was 0.97 (95 % CI 0.93-1.0). One sample was detected on the SHC laboratory developed test (LDT) and not on the Panther Fusion, and had a Ct of 35.9. Conversely, 2 samples were detected on the Panther Fusion and not on the LDT, and had Ct values of 37.2 and 36.6. CONCLUSION: The Panther Fusion SARS-CoV-2 assay and the SHC LDT perform similarly on clinical nasopharyngeal swab specimens. Other considerations, including reagent availability, turnaround time, labor requirements, cost and instrument throughput should guide the decision of which assay to perform.","J Clin Virol","Hogan, Catherine A","Sahoo, Malaya K","Huang, ChunHong","Garamani, Natasha","Stevens, Bryan","Zehnder, James","Pinsky, Benjamin A","32353760"],"abstract":["BACKGROUND: Numerous nucleic acid amplification assays have recently received emergency use authorization (EUA) for the diagnosis of SARS-CoV-2 infection, and there is a need to assess their test performance relative to one another. OBJECTIVES: The aim of this study was to compare the test performance of the Hologic Panther Fusion SARS-CoV-2 assay targeting two regions of open reading frame 1ab (ORF1ab) to a high complexity molecular-based, laboratory-developed EUA from Stanford Health Care (SHC) targeting the SARS-CoV-2 envelope (E) gene. STUDY DESIGN: We performed a diagnostic comparison study by testing nasopharyngeal samples on the two assays. Assay agreement was assessed by overall percent agreement and Cohen's kappa coefficient. RESULTS: A total of 184 nasopharyngeal samples were tested using the two assays, of which 180 showed valid results and were included for the comparative analysis. Overall percent agreement between the assays was 98.3 % (95 % confidence interval (CI) 95.2-99.7) and kappa coefficient was 0.97 (95 % CI 0.93-1.0). One sample was detected on the SHC laboratory developed test (LDT) and not on the Panther Fusion, and had a Ct of 35.9. Conversely, 2 samples were detected on the Panther Fusion and not on the LDT, and had Ct values of 37.2 and 36.6. CONCLUSION: The Panther Fusion SARS-CoV-2 assay and the SHC LDT perform similarly on clinical nasopharyngeal swab specimens. Other considerations, including reagent availability, turnaround time, labor requirements, cost and instrument throughput should guide the decision of which assay to perform."],"journal":"J Clin Virol","authors":["Hogan, Catherine A","Sahoo, Malaya K","Huang, ChunHong","Garamani, Natasha","Stevens, Bryan","Zehnder, James","Pinsky, Benjamin A"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353760","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jcv.2020.104383","keywords":["laboratory-developed test","panther fusion","qiasymphony","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495755747328,"score":363.68127}]}